4.8 Article Proceedings Paper

Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy

期刊

JOURNAL OF CONTROLLED RELEASE
卷 267, 期 -, 页码 100-118

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2017.09.026

关键词

Paclitaxel; Drug delivery; Nanomedicine; Cancer; Chemotherapy

资金

  1. National Science Foundation [DMR 1255281]
  2. National Institutes of Health [NIH/1R21CA191740]
  3. Division Of Materials Research
  4. Direct For Mathematical & Physical Scien [1255281] Funding Source: National Science Foundation

向作者/读者索取更多资源

Paclitaxel (PTX) is one of the most successful drugs ever used in cancer chemotherapy, acting against a variety of cancer types. Formulating PTX with Cremophor EL and ethanol (Taxol (R)) realized its clinical potential, but the formulation falls short of expectations due to side effects such as peripheral neuropathy, hypotension, and hypersensitivity. Abraxane (R), the albumin bound PTX, represents a superior replacement of Taxol (R) that mitigates the side effects associated with Cremophor EL. While Abraxane (R) is now considered a gold standard in chemotherapy, its 21% response rate leaves much room for further improvement. The quest for safer and more effective cancer treatments has led to the development of a plethora of innovative PTX formulations, many of which are currently undergoing clinical trials. In this context, we review recent development of PTX drug delivery systems and analyze the design principles underpinning each delivery strategy. We chose several representative examples to highlight the opportunities and challenges of polymeric systems, lipid-based formulations, as well as prodrug strategies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据